Brief Introduction – Eli Lilly and Company
Eli Lilly has evolved from a traditional pharmaceutical company into one of the most strategically important growth platforms in the global healthcare sector. Through medications such as Mounjaro and Zepbound, as well as a strong pipeline in the areas of diabetes, obesity, oncology, immunology, and neuroscience, the company is increasingly positioning itself at the center of global demand for innovative metabolic therapies.
Today, the investment story is no longer based solely on defensive pharmaceutical sales. It is increasingly driven by:
- GLP-1 therapies for obesity and diabetes,
- the expansion of global production capacities,
- high-margin patent-protected medications,
- pipeline optionality,
- long-term rising healthcare expenditures,
- and scalable profit growth.
At the same time, following the strong share price performance of recent years, Eli Lilly also faces new challenges:
- very high valuation expectations,
- growing competition from Novo Nordisk and other providers,
- production and supply chain risks,
- regulatory pressure on drug prices,
- and the need to ensure long-term pipeline success beyond GLP-1.
Eli Lilly and Company
Analysis Result: 5 out of 5 MUMAKS
Rating
This analysis evaluates Eli Lilly and Company according to the UMBRELLA strategy using the MUMAK method. The evaluation is carried out along five decision phases: Geopolitics, Industry, Fundamentals, Market Sentiment, and Technical Analysis.
Structure: Classification → Key Statement → Rationale → Conclusion
The goal is not to predict the future precisely. The goal is orientation. We contextualize facts, demonstrate causal relationships, and structure a comprehensible decision logic.
We explain – you decide.
Geopolitics
Classification
The geopolitical environment is fundamentally supportive for Eli Lilly. Healthcare, pharmaceutical production, and medical innovation are increasingly viewed as strategically important infrastructure in the US and Europe. At the same time, political discussions regarding drug prices and access to obesity therapies remain a relevant risk.
Key Takeaway
Eli Lilly benefits from the strategic importance of innovative healthcare but remains exposed to long-term regulatory risks in the area of drug pricing.
Rationale
Healthcare innovation holds strategic importance
Governments are increasingly prioritizing national healthcare, pharmaceutical supply chains, and access to innovative therapies. Eli Lilly benefits from this through its strong market position and global medication platform.
Obesity and diabetes remain global growth areas
The globally rising number of diabetes and obesity cases supports long-term demand for effective GLP-1 therapies.
Production capacity becomes a competitive advantage
As demand for GLP-1 medications remains extremely high, production capacities and delivery capabilities are becoming central strategic factors.
Drug prices remain a political risk
The high costs of modern obesity therapies could trigger political pressure, regulatory intervention, and discussions about reimbursement models.
Conclusion
The geopolitical environment remains positive overall. Eli Lilly benefits from globally rising healthcare investments and high demand for innovative therapies, even if regulatory pressure on drug prices remains a long-term risk.
MUMAK.me Assessment Phase 1: Positive = 1 MUMAK
Eli Lilly and Company
Geopolitics Rating: positive
Industry
Assessment
The pharmaceutical and metabolic industry remains structurally attractive. Obesity, diabetes, and metabolic diseases are among the largest long-term healthcare markets worldwide. GLP-1 therapies have massively expanded the addressable market potential for leading pharmaceutical companies.
Key Takeaway
Eli Lilly operates in one of the strongest long-term growth segments of the global healthcare market.
Rationale
Global GLP-1 adoption is accelerating
Demand for modern diabetes and obesity therapies is growing dynamically worldwide — supported by medical necessity, rising prescription numbers, and positive clinical data.
Eli Lilly is among the industry leaders
With Mounjaro and Zepbound, Eli Lilly is one of the world’s leading companies in the GLP-1 market.
Economies of scale create high barriers to entry
Large-scale clinical trials, regulatory experience, production capacities, and global distribution structures create significant competitive advantages.
Additional pipeline opportunities remain significant
In addition to existing GLP-1 products, Eli Lilly possesses further growth potential through new areas of application, oral therapies, and additional pipeline successes.
Conclusion
Eli Lilly is positioned in a structurally attractive growth industry that benefits long-term from obesity therapies, diabetes treatment, and pharmaceutical innovation.
MUMAK.me Assessment Phase 2: Positive = 1 MUMAK
Eli Lilly and Company
Industry Rating: positive
Fundamentals
Assessment
Eli Lilly’s fundamentals remain very strong. Revenue, EBITDA, EBIT, net profit, and free cash flow are developing dynamically, driven by strong demand for GLP-1 medications and rising margins.
Key Takeaway
Eli Lilly is successfully converting the high demand for GLP-1 therapies into exceptional revenue growth, increasing profitability, and strong cash flow development.
Rationale
Revenue growth remains strong
| Key Figure | Latest Result |
|---|---|
| Revenue Growth YoY | USD 15.92 billion |
| Revenue growth QoQ | +9,5 % |
| Revenue growth FY2025 | 44,7% |
| Revenue FY2025 | USD 65.18 billion |
| Main Growth Drivers | GLP-1 / Obesity / Diabetes |
Eli Lilly is benefiting massively from the globally rising demand for obesity and diabetes therapies. Revenue growth remains exceptionally high despite the company’s already significant size.
Profitability remains high
| Key Figure | FY2024 | FY2025 |
|---|---|---|
| EBIT Margin | 17,9 % | 20,9 % |
| Net Margin | 9,6 % | 15,7 % |
| EBITDA Margin | 26,1 % | 28,4 % |
Eli Lilly’s margin structure is improving massively. The company benefits from high GLP-1 demand, premium pricing, economies of scale, and highly profitable patent-protected medications.
Free cash flow growth reflects rising earning power
| Key Figure | Value |
|---|---|
| Free Cash Flow FY’25 | USD 8.97 billion |
| FCF growth YoY | +138,6 % |
| CAPEX FY2025 | USD 16.8 billion |
| FCF margin FY2025 | +13,7 % |
Despite high investments in production capacities, free cash flow is developing very dynamically. This underscores the strong operational scalability of the business model.
Balance Sheet Remains Solid
| Key Figure | Latest Result |
|---|---|
| Net debt FY2025 | USD 35.24 billion |
| Net debt / EBITDA | 1.20x |
| Debt / Free Cash Flow | 3.93x |
| Book value per share | USD 29.57 |
Debt has increased due to high investments but remains well-controlled given the strong EBITDA growth. Balance sheet quality is improving significantly on an operational level.
Capital allocation remains shareholder-friendly
| Key Figure | Current Result |
|---|---|
| Dividend per share FY2025 | USD 6.00 |
| Dividend growth FY2025 | 15,4 % |
| Earnings per share FY2025 | USD 22.95 |
| EPS growth FY2025 | 95,9% |
Eli Lilly combines aggressive growth with increasing distributions. Dividend development reflects the company’s strong earnings momentum.
Conclusion
Eli Lilly combines:
- exceptionally strong revenue growth,
- massive margin expansion,
- rising free cash flow,
- solid balance sheet quality,
- strong GLP-1-driven earnings development,
- and long-term pipeline potential.
The most important factor to watch remains whether the company can defend its GLP-1 leadership position in the long term while sufficiently expanding production capacities.
The combination of structural healthcare growth, high innovative strength, and increasing profitability continues to support Eli Lilly’s long-term value creation potential.
→ MUMAK.me Evaluation Phase 3: positive = 1 MUMAK
Eli Lilly and Company
Fundamentals Rating: positive
News, Analysts, and Market Sentiment
Assessment
The news situation and analyst sentiment remain constructive overall, supported by ongoing GLP-1 momentum, the rising demand for obesity therapies, and Eli Lilly’s strong positioning in the global market for metabolic diseases. At the same time, the stock is reacting with increasing sensitivity to valuation levels, production capacities, and competitive developments.
Key Takeaway
Market sentiment toward Eli Lilly remains clearly positive, as the company is viewed as one of the world’s leading platforms for obesity and diabetes therapies.
Rationale
Analyst sentiment remains constructive
Analyst sentiment toward Eli Lilly remains positive. Consensus estimates reflect high expectations for long-term growth in the field of obesity and diabetes therapies.
Analyst Assessment
| Number of Analysts | ~USD 99 |
| Average Price Target | ~1,200 USD |
| Upside to Average Target | +7,8 % |
| Upper Target | ~1,500 USD |
| Lower Target | ~850 USD |
Detailed Distribution
| Revenue and Profit | |
|---|---|
| Buy | 18 |
| Accumulate | 6 |
| Hold | 5 |
| Reduce | 1 |
| Sell | 1 |
The analyst landscape thus remains clearly positive, as the vast majority of analysts continue to rate the stock as Buy or Outperform.
Recent quarterly figures support the investment story
The most recent quarterly results once again confirmed the strong demand for Mounjaro and Zepbound, high revenue growth, and increasing profitability despite high investments in production capacities.
Valuation expectations remain high
As Eli Lilly is considered one of the most important listed beneficiaries of the global market for obesity therapies, the stock is reacting with increasing sensitivity to changes in growth expectations, prescription trends, and production capacities.
Several growth drivers remain visible
Key potential growth drivers include:
- accelerated global GLP-1 adoption,
- international expansion of obesity therapies,
- additional areas of application,
- development of oral GLP-1 medications,
- expansion of production capacities,
- and further monetization of the medication pipeline.
Conclusion
Market sentiment toward Eli Lilly remains positive, even though expectations are high. The company continues to benefit from strong analyst support and ongoing optimism surrounding obesity and diabetes therapies, while valuation risks and competitive dynamics remain important factors to watch.
MUMAK.me Evaluation Phase 4: Positive = 1 MUMAK
Eli Lilly and Company
Market Sentiment Rating: positive
Technical Analysis
Assessment
Technical analysis structures the timing framework of a position.
Eli Lilly’s technical structure is developing positively again despite intermittent correction phases. The stock benefits from a strong long-term uptrend, which is supported in particular by the enormous demand for GLP-1/obesity medications and high expectations for future growth.
At the same time, the strong price increases of recent quarters are also showing increasing sensitivity to:
- Valuation Level
- profit-taking
- regulatory risks
- competition in the GLP-1 market
However, the current technical structure suggests a continued stabilization within the long-term uptrend rather than a structural phase of weakness.
Key Takeaway
Eli Lilly continues to be in a technically strong long-term uptrend with increasing momentum once again.
The stock is currently showing clear signs of a trend continuation, but at the same time is moving back into a technically more demanding area near important resistance levels and increasingly heightened valuation sensitivity.
Rationale
Development in recent weeks/months
Since May, there has been a significant acceleration of the upward movement back toward the highs.
The long-term trend structure thus remains intact.
Bollinger Bands
The stock was trading along an uptrend at the upper Bollinger Band.
In particular, the strong dynamics in the GLP-1/obesity segment led to a pronounced momentum phase with institutional capital inflows.
After the high in the range of:
~1,109 USD
At the end of last year, there was temporary:
- waning momentum
- consolidation movements
- Increased volatility
- temporary uncertainty in the trend course
The current price is now moving near the upper Bollinger Band again in the range of:
~1,080 USD
This currently signals:
- strong buyer dynamics
- return of institutional demand
- renewed trend acceleration
- possible continuation of the uptrend
The Bollinger structure thus remains:
→ expansively bullish
with continued positive trend control.
RSI
The RSI recently rose significantly and is currently moving in the range of:
~70–71
This reflects:
- strongly positive momentum
- aggressive buying pressure
- institutional capital inflows
- high trend stability
At the same time, the RSI is already approaching overbought areas again.
This means:
- short-term increased risk of overheating
- possible interim consolidations
- but buyers still clearly in control
The RSI currently signals:
→ Uptrend
with increasingly heightened short-term euphoria and potential for pullbacks.
MACD
The MACD lines are in positive territory.
The histogram has recently shown increasing positive momentum again.
This indicates:
- continued trend strength
- renewed momentum acceleration
- strong medium-term market structure
- Return of institutional buyers
point to.
The MACD currently confirms the bullish market phase and supports the probability of further trend continuation.
Conclusion
From a chart perspective, the current pattern looks like:
→ Uptrend → Consolidation → Stabilization → Renewed trend acceleration
Eli Lilly is currently still in a technically strong market phase.
→ Important support levels were successfully defended
→ Momentum indicators confirm strength
→ Uptrend remains intact
→ New highs remain technically possible
The key question now is whether the stock can sustainably hold the zone around:
~1,109 USD
can be overcome sustainably.
A breakout above this could trigger the next major MUMAK wave and further trend acceleration represented by a MUMAK Hypervation.
At the same time, however, the strong rally also increases the probability of short-term consolidations or profit-taking.
The current technical constellation currently continues to favor:
→ Trend continuation and constructive strength
than toward:
→ structural weakness or trend break.
→ MUMAK.me Rating Phase 5: neutral = 1 MUMAK
Eli Lilly and Company
Technical Analysis Rating: positive
Summary
The analysis shows an overall stabilized positive picture with potentially attractive strategic positioning in the long term.
→ Geopolitics → Industry → Fundamental Data → Market Sentiment → Chart Analysis
Eli Lilly benefits in particular from:
- GLP-1 therapies
- obesity medications
- diabetes treatments
- high innovative strength
- increasing production capacities
- strong pipeline
- growing profitability
The investment logic is based on a long-term healthcare and innovation story:
→ Obesity + Diabetes + GLP-1 + Pharma Innovation + Global Healthcare Spending
The focus is increasingly shifting to:
→ global GLP-1 adoption → expansion of production capacities → new indications → pipeline successes → margin expansion → sustainable profit growth
At the same time, Eli Lilly remains confronted with regulatory risks, high valuation, and growing competition – particularly from Novo Nordisk. Long-term development depends significantly on whether the company can maintain its market leadership in the GLP-1 segment and successfully monetize its innovation pipeline.
Overall, Eli Lilly remains fundamentally and strategically excellently positioned and is among the most important growth companies in the global healthcare sector.
Rating According to the MUMAK Method
| Category | Rating |
|---|---|
| Geopolitics | Positive |
| Industry | Positive |
| Fundamentals | Positive |
| News & Sentiment | Positive |
| Technical Analysis | Positive |
